"A key benefit of this new alliance is the combined strengths of technical product research and development with manufacturing and regulatory compliance," said Mike Vaughn, president of Hyalynx. Vaughn added that the clinical efficacy of products sourced through Ash would help it to fulfill requirements for regulatory and scientific issues associated with global product launches. Kentucky-based Hyalynx has forged its name as a distributor of high quality hyaluronate products, including sodium, zinc and calcium derivatives that are used in every type of cosmetic products, as well as eye drops, capsules and soft gels. However, the new venture should see the company expanding its ingredient portfolio significantly. "Ash Ingredients has significant manufacturing, research and development experience that complements the expertise with regulatory affairs of Hyalynx, providing customers with a one-stop resource for acquiring specialty compounds," said Anil Kripalani, president of Ash Ingredients. Ash, which produces ingredients that are non-GMO and non-avian-animal dervived, has also had to fulfill Hyalynx requirements to be cGMO compliant in its manufacturing practices. Combined, the Hyalynx-Ash domestic warehouses will represent 30,000 square feet, with facilities strategically located in New Jersey, North Carolina, California, and Kentucky. The joint-venture will ensure the supply of a portfolio of ingredients that will include sodium hyaluronate, saw palmetto, shea butter, boswellia, garcinia, coleus forskolin, flax seed oil, Coenzyme Q10, Omega 3 and solanesol. The ultimate aim of the venture is to ensure a reliable and seamless supply of such ingredients, backed up by the cost efficient sourcing advantages that aim to ensure pricing is competitive.